At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
afliberceptdrug
Likely dose
aflibercept 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab
In Brief
A Phase 4 clinical trial evaluating aflibercept for Diabetic Retinopathy and Macular Edema. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy, Macular Edema
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionDec 2020
TodayJul 2026
First PostedSep 24, 2015
Enrollment StartOct 1, 2015
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 10.8 years ago
Interventions
afliberceptdrug
aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment